First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

PURPOSE: This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1), and determined the recommended phase II dose. PATIENTS AND METHODS: In total, 189 patients with advanced solid tumors r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Abdul Razak, Albiruni R., Mau-Soerensen, Morten, Gabrail, Nashat Y., Gerecitano, John F., Shields, Anthony F., Unger, Thaddeus J., Saint-Martin, Jean R., Carlson, Robert, Landesman, Yosef, McCauley, Dilara, Rashal, Tami, Lassen, Ulrik, Kim, Richard, Stayner, Lee-Anne, Mirza, Mansoor R., Kauffman, Michael, Shacham, Sharon, Mahipal, Amit
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2016
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5562433/
https://ncbi.nlm.nih.gov/pubmed/26926685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.3949
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados